drugset
drugset / Trial / NCT04171414

A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

NCT04171414 ↗

Phase 3 Completed 62 enrolled Celltrion PPD Development, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

Timeline

Start
2019-09-09
Primary completion
2019-11-04
Completion
2020-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications

rheumatoid arthritis